Insulin Detemir: Nursing Drug Guide, Hypoglycemia & Basal Dosing

Insulin detemir is marketed as Levemir (100 units/mL subcutaneous injection) per FDA labeling. It is a clear, colorless solution—do not use if cloudy, discolored, or particulate. Insulin detemir is not interchangeable with insulin glargine, NPH insulin, insulin lispro, or other insulins without prescriber conversion and closer glucose monitoring.

Insulin detemir is a long-acting human insulin analog indicated to improve glycemic control in adult and pediatric patients with diabetes mellitus per FDA labeling—including type 1 diabetes and type 2 diabetes.

↔On a small screen, swipe or scroll sideways to see the full table.

Like other insulins, insulin detemir lowers blood glucose by stimulating peripheral glucose uptake (especially skeletal muscle and fat) and inhibiting hepatic glucose production per labeling. Its long duration is mediated by slowed absorption from the injection site due to self-association and albumin binding. Nursing relevance: detemir is basal coverage—it continues lowering glucose even when the patient is NPO, which makes meal planning, mealtime insulin, and hypoglycemia surveillance essential.

Individualize and titrate based on metabolic needs, blood glucose monitoring results, and glycemic goals per FDA labeling. Confirm type of diabetes, mealtime insulin orders, renal/hepatic status, and activity level before each dose.

Starting and conversion (FDA labeling)

↔On a small screen, swipe or scroll sideways to see the full table.

Missed dose: Not specified in the reviewed prescribing information—contact prescriber/pharmacy; do not double the next dose without guidance.

↔On a small screen, swipe or scroll sideways to see the full table.

Pretreatment checks

• Verify right patient, drug, dose (units), route, time—independent double-check for high-alert insulin
• Confirm solution is clear and colorless; read label aloud with second nurse when policy requires
• Review point-of-care glucose, recent hypoglycemia, oral intake, and NPO status
• Type 1 diabetes: confirm mealtime rapid-acting insulin plan is in place and not conflicting
• Screen for beta-blockers, alcohol, renal/hepatic impairment, and steroid changes

Contraindications

• During episodes of hypoglycemia
• Hypersensitivity to insulin detemir or excipients (anaphylaxis reported)

Important interactions and factors

↔On a small screen, swipe or scroll sideways to see the full table.

Subcutaneous only: Inject into thigh, upper arm, or abdomen per labeling. Rotate sites within the same region; do not inject into lipodystrophy or localized cutaneous amyloidosis areas. Follow subcutaneous injection and insulin administration protocols.

• Do not dilute or mix detemir with any other insulin or solution
• Do not administer IV or IM unless explicit protocol for another product—detemir is SC
• Never share FlexPen, syringe, or needle between patients—even if needle is changed
• Increase glucose monitoring frequency during insulin regimen changes
• Document product name, units, site, and label verification

• Fasting and between-meal glucose trends toward prescriber targets over days to weeks
• Improved HbA1c when adherence, meal plan, and mealtime insulin (if ordered) align
• Reduced hyperglycemia symptoms without recurrent hypoglycemia
• Weight gain may occur with insulin therapy per labeling—monitor and teach

Severe hypoglycemia can cause seizures, unconsciousness, permanent neurologic injury, or death per labeling. Hold insulin and treat immediately when:

• Symptomatic hypoglycemia or glucose below facility treatment threshold
• Confusion, combativeness, seizure, or loss of consciousness—treat even if beta-blockers mask tachycardia
• Wrong insulin product, wrong dose (especially unit vs mL error), or cloudy/discolored solution administered or suspected
• Persistent dizziness, diaphoresis, or neuroglycopenic symptoms after a basal dose during poor oral intake
• Anaphylaxis or serious hypersensitivity (discontinue per prescriber; treat per emergency protocol)
• Significant hypokalemia risk with insulin therapy—monitor per prescriber when on potassium-lowering therapy

↔On a small screen, swipe or scroll sideways to see the full table.

Excess insulin relative to food intake or energy expenditure may cause severe, prolonged, life-threatening hypoglycemia and hypokalemia per FDA labeling.

Management

• Mild hypoglycemia: Oral glucose; adjust insulin dose, meals, or activity per prescriber
• Severe hypoglycemia with coma, seizure, or neurologic impairment: glucagon for emergency use or concentrated intravenous glucose
• After apparent recovery, continue observation and additional carbohydrate—hypoglycemia may recur
• Correct hypokalemia appropriately if present
• Contact local poison control or toxicology services per facility protocol
• No specific antidote beyond treatment of hypoglycemia and supportive care is listed

• Levemir vs Lantus (glargine) vs other basal insulins—different products; conversion requires prescriber plan and monitoring
• Clear detemir vs cloudy NPH—appearance check prevents wrong insulin selection
• 100 units/mL concentration—U-100 syringe or pen; never withdraw with tuberculin or IV syringe scaled in mL alone
• Units vs mL—10 units = 0.1 mL at U-100; independent double-check high-alert dose
• Basal vs rapid-acting—do not substitute mealtime insulin for detemir or vice versa
• Shared pens/syringes—never between patients (infection and dosing error risk)

↔On a small screen, swipe or scroll sideways to see the full table.

↔On a small screen, swipe or scroll sideways to see the full table.

Monitor

• Capillary or laboratory glucose per prescriber and facility protocol—especially before meals, at bedtime, and overnight when hypoglycemia risk is high
• Signs of hypoglycemia and hyperglycemia
• Potassium when clinically indicated (diuretics, IV insulin elsewhere, cardiac risk)
• Injection sites for lipodystrophy or localized amyloidosis
• HbA1c per diabetes care plan

Document

• Insulin product verification, dose in units, route, site, and time
• Hypoglycemia treatment, recurrence, and prescriber/pharmacy notification
• NPO status, meal intake, and hold/reduction orders during procedures
• Regimen changes and patient education provided

• Check the insulin label and appearance every injection—detemir must be clear and colorless
• Know hypoglycemia symptoms; beta-blockers may hide shaking and fast heartbeat—check glucose if you feel weak or confused
• Carry rapid-acting carbohydrate; family should know when to give glucagon or seek emergency care
• Never share pens or needles; rotate injection sites
• Do not mix detemir with other insulins in the same syringe
• Ask your care team how to adjust for illness, NPO instructions, or exercise before changing doses

Do not give and contact the prescriber/pharmacist when:

Hold parameters may vary by institutional protocol. Follow prescriber orders, pharmacy guidance, and facility high-alert insulin policy.

Rehearse NCLEX-style clinical judgment practice for insulin detemir hypoglycemia and high-alert administration using a tabbed inpatient case (MAR, labs, vitals, nursing notes), then priority action, cue recognition (SATA), glucose trend interpretation, matrix urgency sorting, product-safety MCQ, and documentation cloze—recognise cues → analyse → prioritise → act → evaluate outcomes.

62-year-old with type 2 diabetes and coronary disease is admitted for same-day cholecystectomy. Home regimen: insulin detemir 22 units at bedtime and insulin aspart with meals. In hospital: detemir 18 units at 2100, insulin aspart per carb ratio, and carvedilol 25 mg twice daily. NPO after midnight for surgery tomorrow. The nurse reviews the evening medication pass.

This medication guide is written and reviewed using NurseOnShift editorial and clinical review standards.

• Editorial Policy
• Medical Review Process
• Disclaimer

Educational use only. This content does not replace clinical judgment, prescriber orders, pharmacist guidance, product labeling, or institutional protocols.